Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
NEW YORK , July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during t
Sarepta Therapeutics: What's Happening With SRPT Stock?
06:35am, Thursday, 17'th Jul 2025
Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring plan
Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box' Warning Are Good News.
06:03am, Thursday, 17'th Jul 2025
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene therapy Elevidys.
Sarepta: Finally, A Little Relief For Bulls; I Expect More
03:58am, Thursday, 17'th Jul 2025
Sarepta's turnaround is just beginning, with decisive management actions like layoffs boosting confidence and saving $100 million annually. The market had priced in the worst for Elevidys, but the FDA
Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult
11:34pm, Wednesday, 16'th Jul 2025
Sarepta stock catapulted Wednesday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
Sarepta to cut 500 jobs after gene therapy setback
04:21pm, Wednesday, 16'th Jul 2025
Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after two recent deaths of patients who had received its gene therapy, Elevidys.
RADNOR, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United S
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed to prio
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
11:13am, Wednesday, 16'th Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired
Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi & Korsinsky about pending Class Action - SRPT
09:00am, Tuesday, 15'th Jul 2025
NEW YORK , July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
04:22pm, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023
